Drug · CHEMBL3137343
Comparisons in its trials730
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 730
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Biomarker Cohort vs Non-biomarker Cohort: deaths from any cause | 364 of 618 | 3,780 of 4,661 | 5,279 | NCT05834348 | Trial comparisons |
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE) | 267 of 785 | 206 of 787 | 1,572 | NCT03675737 | Trial comparisons |
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Experienced an Adverse Event (AE) | 776 of 785 | 771 of 787 | 1,572 | NCT03675737 | Trial comparisons |
| Pembrolizumab/Vibostolimab vs Pembrolizumab: deaths from any cause | 6 of 701 | 1 of 701 | 1,402 | NCT05665595 | Trial comparisons |
| Pembrolizumab/Vibostolimab vs Pembrolizumab: serious adverse events | 109 of 698 | 57 of 700 | 1,398 | NCT05665595 | Trial comparisons |
| FDA Approved Regimen vs MK-3475 (Pembrolizumab): deaths from any cause | 130 of 654 | 131 of 647 | 1,301 | NCT02506153 | Trial comparisons |
| Pembrolizumab vs Chemotherapy (SOC Treatment): Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) | 126 of 636 | 93 of 615 | 1,251 | NCT02220894 | Trial comparisons |
| Pembrolizumab vs Chemotherapy (SOC Treatment): Number of Participants Who Experienced At Least One Adverse Event (AE) | 608 of 636 | 606 of 615 | 1,251 | NCT02220894 | Trial comparisons |
| Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT: deaths from any cause | 105 of 626 | 93 of 625 | 1,251 | NCT04191096 | Trial comparisons |
| Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT: serious adverse events | 252 of 625 | 145 of 625 | 1,250 | NCT04191096 | Trial comparisons |
| Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide: Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE) | 115 of 615 | 50 of 620 | 1,235 | NCT03834493 | Trial comparisons |
| Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide: Number of Participants Who Experience an Adverse Event (AE) | 594 of 615 | 596 of 620 | 1,235 | NCT03834493 | Trial comparisons |
| FDA Approved Regimen vs MK-3475 (Pembrolizumab): serious adverse events | 23 of 565 | 125 of 639 | 1,204 | NCT02506153 | Trial comparisons |
| Pembrolizumab vs Placebo: deaths from any cause | 136 of 590 | 154 of 587 | 1,177 | NCT02504372 | Trial comparisons |
| Pembrolizumab vs Placebo: Number of Participants Who Experienced an Adverse Event (AE) | 556 of 580 | 529 of 581 | 1,161 | NCT02504372 | Trial comparisons |
| Pembrolizumab vs Placebo: Number of Participants Who Discontinued Study Treatment Due to an AE | 116 of 580 | 34 of 581 | 1,161 | NCT02504372 | Trial comparisons |
| Pembrolizumab vs Placebo: serious adverse events | 142 of 580 | 90 of 581 | 1,161 | NCT02504372 | Trial comparisons |
| Arm A (Pembrolizumab+Gemcitabine+Cisplatin) vs Arm B (Placebo+Gemcitabine+Cisplatin): Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE) | 138 of 529 | 122 of 534 | 1,063 | NCT04003636 | Trial comparisons |
| Arm A (Pembrolizumab+Gemcitabine+Cisplatin) vs Arm B (Placebo+Gemcitabine+Cisplatin): Number of Participants Who Experience One or More Adverse Events (AE) | 524 of 529 | 532 of 534 | 1,063 | NCT04003636 | Trial comparisons |
| Pembrolizumab + CCRT vs Placebo + CCRT: deaths from any cause | 107 of 529 | 140 of 531 | 1,060 | NCT04221945 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL3137343/comparisons